HSA
CRMD icon

Hussman Strategic Advisors’s CorMedix CRMD Stock Holding History

Hussman Strategic Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-210,000
Closed -$2.44M – 289
2025
Q4 		$2.44M Sell
210,000
-105,000
-33% -$1.16M 0.59% 58
2025
Q3 		$3.66M Buy
315,000
+252,000
+400% +$3.05M 0.79% 13
2025
Q2 		$776K Buy
+63,000
New +$695K 0.18% 161

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Hussman Strategic Advisors's CRMD Position: Q1 2026 in Review

Hussman Strategic Advisors sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 210,000 shares — an estimated $2.44M sold.

Hussman Strategic Advisors first reported a position in CRMD in Q2 2025 and held it in 3 quarters. The position peaked at $3.66M in Q3 2025. 188 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Hussman Strategic Advisors reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 210,000 CorMedix shares in Q1 2026, an estimated $2.44M.
  • Hussman Strategic Advisors first reported a position in CorMedix in Q2 2025 and held it in 3 quarters.
  • Hussman Strategic Advisors's CorMedix position peaked at $3.66M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.